TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.


Options:
A: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg
B: Arm Label: RAD001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): RAD001 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C
D: Arm Label: Interleukin-2, interferon, bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Interleukin-2 and interferon-alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interleukin-2, Drug: Interferon Alfa-2b | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): Interleukin-2 and interferon-alfa | Intervention Type: DRUG; Name: Interferon Alfa-2b; Assigned to Arm(s): Interleukin-2 and interferon-alfa | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Interleukin-2, interferon, bevacizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.


Options:
A: Arm Label: Lenvatinib; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib | Arm Label: Lenvatinib plus Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib, Lenvatinib plus Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus, Lenvatinib plus Everolimus
B: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg
C: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L
D: Arm Label: Arm 1: nivolumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 2: nivolumab - 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 3: nivolumab - 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 1: nivolumab - 0.3 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 2: nivolumab - 2.0 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 3: nivolumab - 10.0 mg/kg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)
Brief Summary: This is a single arm phase II trial focused on how dabrafenib and trametinib before and after surgery works in treating patients with stage IIIB-C melanoma that has a specific mutation in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving dabrafenib and trametinib after surgery may kill any remaining tumor cells.


Options:
A: Arm Label: Treatment (dabrafenib, trametinib, surgery); Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Other: Laboratory Biomarker Analysis, Procedure: Therapeutic Conventional Surgery, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery)
B: Arm Label: Surgery; Type: OTHER; Interventions: Procedure: Immediate surgical resection of melanoma lesion(s) | Arm Label: Talimogene Laherparepvec; Type: EXPERIMENTAL; Interventions: Drug: Talimogene Laherparepvec | Intervention Type: DRUG; Name: Talimogene Laherparepvec; Assigned to Arm(s): Talimogene Laherparepvec | Intervention Type: PROCEDURE; Name: Immediate surgical resection of melanoma lesion(s); Assigned to Arm(s): Surgery
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery of the tumor, Drug: Infusion with ipilimumab 3 mg/kg q3wks, Drug: Infusion with nivolumab 1 mg/kg q3wks | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery of the tumor, Drug: Infusion with ipilimumab 3 mg/kg q3wks, Drug: Infusion with nivolumab 1 mg/kg q3wks | Intervention Type: PROCEDURE; Name: Surgery of the tumor; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Infusion with ipilimumab 3 mg/kg q3wks; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Infusion with nivolumab 1 mg/kg q3wks; Assigned to Arm(s): Arm A, Arm B
D: Arm Label: Dabrafenib and Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and Trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and Trametinib

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)
Brief Summary: This is a single arm phase II trial focused on how dabrafenib and trametinib before and after surgery works in treating patients with stage IIIB-C melanoma that has a specific mutation in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving dabrafenib and trametinib after surgery may kill any remaining tumor cells.


Options:
A: Arm Label: Treatment (dabrafenib, trametinib, surgery); Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Other: Laboratory Biomarker Analysis, Procedure: Therapeutic Conventional Surgery, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery)
B: Arm Label: Dostarlimab (TSR-042) (singly); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) (singly) | Arm Label: Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) and TSR-022 (combination) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) (singly); Assigned to Arm(s): Dostarlimab (TSR-042) (singly) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) and TSR-022 (combination); Assigned to Arm(s): Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
D: Arm Label: Imiquimod; Type: EXPERIMENTAL; Interventions: Drug: Imiquimod cream + surgery | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + surgery | Intervention Type: DRUG; Name: Imiquimod cream + surgery; Assigned to Arm(s): Imiquimod | Intervention Type: DRUG; Name: Placebo + surgery; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selective or Stepwise Removal of Deep Caries in Deciduous Molars: A Multi-center Randomized Controlled Trial
Brief Summary: Background: For treating deep caries lesions, selective or stepwise, i. e. one- and two-step incomplete excavation seems advantageous compared with complete caries removal. However, current evidence regarding the success, as defined by not requiring any re-treatments, or survival of teeth after different excavations is insufficient for definitive recommendation, especially when treating deciduous teeth. Moreover, restoration integrity has not been comparatively analyzed longitudinally, and neither patients', dentists' or parents' preferences nor the clinical long-term costs emanating from both initial and re-treatments have been reported yet.

Our primary hypothesis is that success rates differ significantly between selectively and stepwise excavated teeth. Secondary hypotheses are that restoration integrity is assumed to significantly differ between selectively and stepwise excavated teeth.


Options:
A: Arm Label: PP; Type: EXPERIMENTAL; Interventions: Procedure: PP | Arm Label: DPC; Type: OTHER; Interventions: Procedure: DPC | Intervention Type: PROCEDURE; Name: PP; Assigned to Arm(s): PP | Intervention Type: PROCEDURE; Name: DPC; Assigned to Arm(s): DPC
B: Arm Label: CHEMOMECHANICAL CARIES REMOVAL; Type: EXPERIMENTAL; Interventions: Procedure: Chemomechanical Caries Removal | Arm Label: conventional method; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional method | Intervention Type: PROCEDURE; Name: Chemomechanical Caries Removal; Assigned to Arm(s): CHEMOMECHANICAL CARIES REMOVAL | Intervention Type: PROCEDURE; Name: Conventional method; Assigned to Arm(s): conventional method
C: Arm Label: Simple Prevention; Type: EXPERIMENTAL; Interventions: Device: Silver Diamine Fluoride, Device: Fluoride Varnishes | Arm Label: Complex prevention; Type: ACTIVE_COMPARATOR; Interventions: Device: Fluoride Varnishes, Device: Glass Ionomer | Intervention Type: DEVICE; Name: Silver Diamine Fluoride; Assigned to Arm(s): Simple Prevention | Intervention Type: DEVICE; Name: Fluoride Varnishes; Assigned to Arm(s): Complex prevention, Simple Prevention | Intervention Type: DEVICE; Name: Glass Ionomer; Assigned to Arm(s): Complex prevention
D: Arm Label: Selective removal; Type: EXPERIMENTAL; Interventions: Procedure: Selective removal | Arm Label: Stepwise removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Stepwise removal | Intervention Type: PROCEDURE; Name: Selective removal; Assigned to Arm(s): Selective removal | Intervention Type: PROCEDURE; Name: Stepwise removal; Assigned to Arm(s): Stepwise removal

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment
Brief Summary: This is a study describing changes in inflammation of the airways in asthmatics before and after smoking cessation and steroid treatment.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
C: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
D: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment
Brief Summary: This is a study describing changes in inflammation of the airways in asthmatics before and after smoking cessation and steroid treatment.


Options:
A: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management
D: Arm Label: SAMe 800; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-Adenosyl-L-Methionine | Arm Label: SAMe 1600; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-Adenosyl-L-Methionine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: S-Adenosyl-L-Methionine; Assigned to Arm(s): SAMe 800 | Intervention Type: DRUG; Name: S-Adenosyl-L-Methionine; Assigned to Arm(s): SAMe 1600 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment
Brief Summary: This is a study describing changes in inflammation of the airways in asthmatics before and after smoking cessation and steroid treatment.


Options:
A: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment
Brief Summary: This is a study describing changes in inflammation of the airways in asthmatics before and after smoking cessation and steroid treatment.


Options:
A: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment
Brief Summary: This is a study describing changes in inflammation of the airways in asthmatics before and after smoking cessation and steroid treatment.


Options:
A: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2
C: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D